DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for restrictive dermopathy 2 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRestrictive dermopathy 2 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for restrictive dermopathy 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lamin A/C (LMNA) — LMNA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6JLB · 3.205 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Restrictive dermopathy 2 is a lethal autosomal recessive disorder caused by biallelic loss-of-function mutations in ZMPSTE24. A 2009 report described the first molecularly confirmed case in a stillborn fetus from a consanguineous Iranian family, identifying a homozygous one-base insertion in ZMPSTE24 exon 9 (c.1085-1086insT). The authors stated that increasing awareness could help diagnose suspected cases, offer carrier testing, and provide prenatal diagnosis to prevent further affected births. No treatment was discussed.
A 2013 report of two siblings in one family described a female neonate with mild characteristic presentations who survived for 16 days, and a male stillborn neonate with typical severe features. Skin biopsy in the stillborn showed typical histological findings, and genetic study revealed a homozygous nonsense mutation in exon 6 of ZMPSTE24. The authors noted that the exact pathogenic mechanism remains poorly understood, and that studies on mutations in lamin A and ZMPSTE24 may help direct future therapeutic approaches, but no therapy was tested.
A 2023 study identified a homozygous frameshift mutation in ZMPSTE24 (c.28_29insA) in two consanguineous Pakistani families who had mandibuloacral dysplasia with type B lipodystrophy (MADB), a milder phenotype, rather than lethal restrictive dermopathy. Functional analysis showed that alternative translation initiation sites, including one newly formed at the insertion site, prevented complete loss of protein function, explaining the milder outcome. The authors concluded that creation of new start codons through N-terminal mutations should be considered in variant interpretation. No drug or treatment was tested in any of these studies.
What is still missing: no clinical trials, no drug candidates tested in patients, no animal model data for any therapeutic intervention, and no systematic patient registry to enable future studies. The disease is ultra-rare, which limits funding and trial design, and patient stratification by residual ZMPSTE24 activity may be needed to distinguish lethal from milder presentations.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Saudi Medical Journal · 2009 · 10 citations
Restrictive dermopathy. Molecular diagnosis of restrictive dermopathy in a stillborn fetus from a consanguineous Iranian family
AbstractRestrictive dermopathy (RD), is an autosomal recessive lethal human genetic disorder. It is characterized by intrauterine growth retardation, tight and rigid skin with erosions, multiple joint contractures, lung hypoplasia, prominent superficial vasculature, and epidermal hyperkeratosis. In the present report, we describe the first case of restrictive dermopathy in a stillborn fetus of Iranian origin, confirmed by molecular genetic diagnosis. In the index case (G-30159), a homozygous one base insertion in ZMPSTE24 exon 9 (c.1085-1086insT) was identified.We believe that by increasing awareness of this disease in clinicians, gynecologists, and pathologists, we may be able to help families who have had suspected cases of restrictive dermopathy be diagnosed, and offer molecular testing in carriers, and prenatal diagnosis to prevent the occurrence of further affected cases.
AbstractRestrictive dermopathy (RD) is a rare and lethal autosomal recessive syndrome characterized by very tight, thin, and easily eroded skin and contracture of joints. We present two siblings in a family. Case 1, a female neonate, showed mild characteristic presentations of RD and survived for 16 days, and Case 2, a male neonate, was stillborn with typical severe features of RD. His skin biopsy showed typical histological findings, and genetic study revealed a homozygous nonsense mutation on the exon 6 of zinc metalloproteinase STE24 (ZMPSTE24). The exact pathogenic mechanism of RD remains poorly understood. The most recent studies on mutations in lamin A and/or ZMPSTE24 have shed some light on the pathophysiology of RD and may help direct the development of future therapeutic approaches.
Clinical Genetics · 2023 · 1 citations · open access
Analysis of a non‐lethal biallelic frameshift mutation in <scp><i>ZMPSTE24</i></scp> reveals utilization of alternative translation initiation codons
AbstractRestrictive dermopathy (RD) is a lethal condition caused by biallelic loss-of-function mutations in ZMPSTE24, whereas mutations preserving residual enzymatic activity of the ZMPSTE24 protein lead to the milder mandibuloacral dysplasia with type B lipodystrophy (MADB) phenotype. Remarkably, we identified a homozygous, presumably loss-of-function mutation in ZMPSTE24 [c.28_29insA, p.(Leu10Tyrfs*37)] in two consanguineous Pakistani families segregating MADB. To clarify how lethal consequences are prevented in affected individuals, functional analysis was performed. Expression experiments supported utilization of two alternative translation initiation sites, preventing complete loss of protein function consistent with the relatively mild phenotypic outcome in affected patients. One of these alternative start codons is newly formed at the insertion site. Our findings indicate that the creation of new potential start codons through N-terminal mutations in other disease-associated genes should generally be taken into consideration in the variant interpretation process.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
